Verastem Oncology

372 articles with Verastem Oncology

• Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

  12/7/2019

  Duvelisib Achieves Overall Response Rate of 62% in Patients with Relapsed or Refractory PTCL with Manageable Safety Profile in Initial Phase of PRIMO Trial

• Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care Award

  11/13/2019

  Verastem, Inc., announced that Andrei Shustov, M.D., Professor of Medicine and Hematology, University of Washington, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center and President and Founder of the T-Cell Leukemia and Lymphoma Foundation has been selected to receive the Company’s Innovation in Care Award.

• Verastem Oncology Announces Private Exchange of Approximately $114.3 Million of its 5.00% Convertible Senior Notes due 2048 for 5.00% Convertible Senior Second Lien Notes Due 2048

  11/12/2019

  The exchange is expected to close on November 14, 2019, subject to customary closing conditions.

• Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress

  10/29/2019

  Company Reports $9 Million in Total Revenue, including $4.0 Million in Net Product Revenue from COPIKTRA®; Reaffirms FY2019 Revenue Guidance

• Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress

  10/23/2019

  Verastem, Inc. announced that five posters highlighting clinical data for COPIKTRA™ will be presented at the Lymphoma & Myeloma 2019 International Congress taking place October 23-26, 2019, in New York City.

• Verastem Oncology to Announce Third Quarter 2019 Financial Results and Corporate Update on October 29, 2019

  10/17/2019

  Verastem, Inc. announced that the Company will host a conference call and webcast on Tuesday, October 29, 2019 at 4:30 p.m.

• Verastem Oncology Announces Dosing of First Patient in Yakult Honsha Co., Ltd.’s Japanese Bridging Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  10/7/2019

  Verastem, Inc., announced that its partner Yakult Honsha Co., Ltd. has dosed the first patient in a Phase 1b Japanese bridging study evaluating COPIKTRA® in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma following at least one prior therapy.

• Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct. 4, 2019

  10/4/2019

  Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, announced the grant of options to purchase 126,363 shares of its common stock to ten new employees.

• Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma

  10/3/2019

  Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced duvelisib (COPIKTRATM) has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of T-Cell lymphoma.

• Verastem Oncology Presents New Preclinical Duvelisib Data at the 5th International Conference on New Concepts in Lymphoid Malignancies

  10/3/2019

  Duvelisib’s Dual Inhibition of PI3K-Delta and PI3K-Gamma Inhibits Migration and Proliferation of Mantle Cell Lymphoma Cells More Effectively Than PI3K-Delta Alone in Preclinical Models

• Verastem Oncology to Present at the Cantor 2019 Global Healthcare Conference

  9/26/2019

  Verastem, Inc. announced that the Company will present at the Cantor 2019 Global Healthcare Conference on Thursday, October 3, 2019 at 8:20 a.m. EDT in New York, NY.

• Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the 18th Annual International Workshop on Chronic Lymphocytic Leukemia

  9/20/2019

  Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that three posters highlighting clinical data for COPIKTRA™ (duvelisib) will be presented at the 18th Annual International Workshop on Chronic Lymphocytic Leukemia taking place September 20-23, 2019, in Edinburgh, UK.

• Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Society of Hematologic Oncology 2019 Annual Meeting

  9/3/2019

  Verastem, Inc. announced that four posters highlighting clinical data for COPIKTRA™ will be presented at the Society of Hematologic Oncology 2019 Annual Meeting taking place September 11-14, 2019, in Houston.

• Verastem Oncology to Present at the 21st Annual H.C. Wainwright Global Investment Conference

  9/3/2019

  Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 21st Annual H.C. Wainwright Global Investment Conference on Tuesday,

• Verastem Oncology Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress

  8/1/2019

  Verastem, Inc. (Nasdaq: VSTM), operating as Verastem Oncology (or “the Company”), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today reported financial results for the three months ended June 30, 2019, and provided an overview of recent accomplishments and clinical development progress for duvelisib (COPIKTRA®).

• Verastem Oncology Appoints Brian Stuglik as Chief Executive Officer

  7/29/2019

  Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Brian Stuglik, a member of the Board of Directors, has been named Chief Executive Officer (CEO).

• Verastem Oncology to Announce Second Quarter 2019 Financial Results and Corporate Update on August 1, 2019

  7/25/2019

  Verastem, Inc. announced that the Company will host a conference call and webcast on Thursday, August 1, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June 30, 2019.

• Verastem Oncology Signs an Exclusive License Agreement with Sanofi for the Development and Commercialization of COPIKTRA® (duvelisib) in Russia and CIS, Turkey, the Middle East and Africa

  7/25/2019

  Verastem, Inc. (NASDAQ: VSTM) operating as Verastem Oncology, (or “the Company”), today announced their entry into an exclusive licensing agreement with Sanofi to develop and commercialize Verastem Oncology’s COPIKTRA® (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, for the treatment of all oncology indications in Russia and CIS, Turkey, the Middle East and Africa.

• Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 3, 2019

  7/3/2019

  Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, announced the grant of options to purchase 104,000 shares of its common stock to five new employees.

• Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on Malignant Lymphoma

  6/21/2019

  Verastem, Inc. announced an oral presentation highlighting supportive Phase 1 clinical data for duvelisib in patients with relapsed or refractory peripheral T-cell lymphoma at the 2019 International Conference on Malignant Lymphoma being held June 18-22, 2019, in Lugano, Switzerland.